{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:01:14Z","timestamp":1769094074151,"version":"3.49.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>We aimed to investigate the clinical value of allograft biopsy performed long after renal transplantation. We retrospectively evaluated 99 allograft biopsies in recipients with transplantation vintages of 10\u00a0years or longer. Mixed-effects model showed that 1-year estimated glomerular filtration rate (eGFR) slopes after biopsy were significantly greater than those before biopsy [\u22123.13, \u22124.42\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\/year, <jats:italic>p<\/jats:italic> = 0.01]. Renal biopsy changed the treatment strategies in more than half of the patients. Improvement in eGFR slopes was pronounced in 51 patients with treatment modification based on the biopsy results [2.27 (95% confidence interval (CI): 0.66, 3.89) mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\/year], whereas no improvement was observed in those without [0.33 (95% CI: \u22121.05, 1.71) mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\/year, P<jats:sub>interaction<\/jats:sub> = 0.001]. Among the treatment modifications, enhancement of immunosuppression (IS) led to the most remarkable improvement in eGFR slope. Patients with g scores \u22652 were more likely to receive IS enhancement than those with g scores = 0 [odds ratio; 15.0 (95% CI: 1.65, 136)]. Patients with active glomerulitis (g \u2265 1) without chronicity (cg \u2264 1) showed the most significant improvement in eGFR slope. Given the prevalence of active glomerulitis (g \u2265 1, 21%), which is responsive to treatment even long after transplantation, and the observed magnitude of eGFR slope improvement, renal biopsy can indeed improve allograft prognosis.<\/jats:p>","DOI":"10.3389\/ti.2024.13022","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T10:42:29Z","timestamp":1721299349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Impacts of Allograft Biopsy in Renal Transplant Recipients 10\u00a0Years or Longer After Transplantation"],"prefix":"10.3389","volume":"37","author":[{"given":"Tomoko","family":"Namba-Hamano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yonishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.kint.2018.05.018","article-title":"Analyses of the Short- and Long-Term Graft Survival After Kidney Transplantation in Europe Between 1986 and 2015","volume":"94","author":"Coemans","year":"2018","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ajt.15672","article-title":"OPTN\/SRTR 2018 Annual Data Report: Kidney","volume":"20","author":"Hart","year":"2020","journal-title":"Am J Transpl"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical Recommendations for Long-Term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3389\/fimmu.2019.01944","article-title":"Recurrent and De Novo Glomerulonephritis After Kidney Transplantation","volume":"10","author":"Lim","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transpl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.2020081215","article-title":"Exploring the Complexity of Death-Censored Kidney Allograft Failure","volume":"32","author":"Mayrdorfer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: Revised Diagnostic Criteria for Chronic Active T Cell-Mediated Rejection, Antibody-Mediated Rejection, and Prospects for Integrative Endpoints for Next-Generation Clinical Trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transpl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T Cell- and Antibody-Mediated Rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transpl"},{"key":"B10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transpl"},{"key":"B11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised Equations for Estimated GFR From Serum Creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in Albuminuria and Subsequent Risk of End-Stage Kidney Disease: An Individual Participant-Level Consortium Meta-Analysis of Observational Studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in Albuminuria as a Surrogate Endpoint for Progression of Kidney Disease: A Meta-Analysis of Treatment Effects in Randomised Clinical Trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"817127","DOI":"10.3389\/fmed.2022.817127","article-title":"Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection","volume":"9","author":"Borski","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1744-9987.2009.00789.x","article-title":"An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2007)","volume":"13","author":"Nakai","year":"2009","journal-title":"Ther Apher Dial"},{"key":"B18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/TP.0000000000000606","article-title":"Long-Term Kidney Allograft Survival in Patients With Transplant Glomerulitis","volume":"99","author":"Nabokow","year":"2015","journal-title":"Transplantation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ki.2015.64","article-title":"The Diffuse Extent of Peritubular Capillaritis in Renal Allograft Rejection Is an Independent Risk Factor for Graft Loss","volume":"88","author":"Kozakowski","year":"2015","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1681\/ASN.2015010062","article-title":"Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study","volume":"27","author":"Naesens","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1600-6143.2012.04304.x","article-title":"Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure","volume":"13","author":"Naesens","year":"2013","journal-title":"Am J Transpl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transpl"},{"key":"B23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/01.TP.0000437177.40551.f4","article-title":"Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-Incompatible Transplant Recipients","volume":"97","author":"Bagnasco","year":"2014","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1111\/ajt.15088","article-title":"The Relationship Between Pathologic Lesions of Active and Chronic Antibody-Mediated Rejection in Renal Allografts","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transpl"},{"key":"B25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of Chronic Antibody Mediated Rejection With Intravenous Immunoglobulins and Rituximab: A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transpl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1111\/j.1600-6143.2011.03647.x","article-title":"Early Ultrastructural Changes in Renal Allografts: Correlation With Antibody-Mediated Rejection and Transplant Glomerulopathy","volume":"11","author":"Haas","year":"2011","journal-title":"Am J Transpl"},{"key":"B28","doi-asserted-by":"publisher","first-page":"101819","DOI":"10.1016\/j.eclinm.2022.101819","article-title":"Optimized Immunosuppression to Prevent Graft Failure in Renal Transplant Recipients With HLA Antibodies (OuTSMART): A Randomised Controlled Trial","volume":"56","author":"Stringer","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfs472","article-title":"The Long-Term Outcome of Renal Transplantation of IgA Nephropathy and the Impact of Recurrence on Graft Survival","volume":"28","author":"Moroni","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"B30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12882-018-0858-9","article-title":"Successful Treatment of Recurrent Immunoglobulin a Nephropathy Using Steroid Pulse Therapy Plus Tonsillectomy 10 Years After Kidney Transplantation: A Case Presentation","volume":"19","author":"Katsumata","year":"2018","journal-title":"BMC Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13730-014-0111-8","article-title":"Recurrent IgA Nephropathy Complicated With Crohn's Disease After Renal Transplantation","volume":"3","author":"Hasegawa","year":"2014","journal-title":"CEN Case Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13730-013-0098-6","article-title":"Five Cases of Tonsillectomy and Steroid Pulse Therapy for Recurrent Immunoglobulin A Nephropathy After Kidney Transplantation","volume":"3","author":"Hoshino","year":"2014","journal-title":"CEN Case Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/nep.12151","article-title":"Tonsillectomy Ameliorates Histological Damage of Recurrent Immunoglobulin A Nephropathy After Kidney Transplantation","volume":"18","author":"Hotta","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A Comparison of Tacrolimus (FK506) and Cyclosporine for Immunosuppression After Cadaveric Renal Transplantation. FK506 Kidney Transplant Study Group","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00007890-200003150-00028","article-title":"Randomized Trial of Tacrolimus (Prograf) in Combination With Azathioprine or Mycophenolate Mofetil Versus Cyclosporine (Neoral) With Mycophenolate Mofetil After Cadaveric Kidney Transplantation","volume":"69","author":"Johnson","year":"2000","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1111\/j.1600-6143.2011.03718.x","article-title":"Specificity of Histological Markers of Long-Term CNI Nephrotoxicity in Kidney-Transplant Recipients Under Low-Dose Cyclosporine Therapy","volume":"11","author":"Snanoudj","year":"2011","journal-title":"Am J Transpl"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients","volume":"9","year":"2009","journal-title":"Am J Transpl"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T10:42:33Z","timestamp":1721299353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":39,"alternative-id":["10.3389\/ti.2024.13022"],"URL":"https:\/\/doi.org\/10.3389\/ti.2024.13022","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"article-number":"13022"}}